Brief: Hansa Biopharma Q2 Operating Loss At SEK 132.4 Million
15/07/2021 07:08
July 15 (Reuters) - Hansa Biopharma AB HNSA.ST :
* Q2 REVENUE SEK 4.5 MILLION
* Q2 OPERATING PROFIT AT SEK -132.4 MILLION
Source text for Eikon: ID:nWkr4zKfpZ
Further company coverage: HNSA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS